Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVE plus cTACE, camrelizumab, and apatinib for conversion therapy in initially unresectable hepatocellular carcinoma
ChiCTR2200061506Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, Rivoceranib, atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Successfully conversion rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200061506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061506.